Imagine having a tiny, living replica of a patient's liver on a chip. Instead of guessing how different medications might clash in an elderly person's body, doctors can test those drugs on this chip first. It's like a dress rehearsal for a prescription to ensure the treatment is safe and effective for that specific person.
Elderly patients often take multiple medications, leading to dangerous, unknown drug interactions. Currently, there is no high-throughput platform to test these specific combinations on a patient's own cells before prescribing.
An integrated microphysiological system (MPS) for cell culture and a set of compact, modular microscopes for long-term imaging of patient-specific biopsies.
If you are a drug development firm dealing with unpredictable drug-drug interactions in aging populations — this project developed an integrated microphysiological system (MPS) that allows testing of novel medicines for NAFLD within typical polypharmacy contexts to determine interactions.
If you are a personalized medicine lab dealing with the lack of high-throughput tools for patient-specific biopsies — this project developed a modular microscopic imaging platform that monitors cellular responses to multiple drug combinations in a parallelized fashion.
If you are a geriatric clinic dealing with high hospital admission rates due to unknown drug interactions — this project developed a system to determine individual responses of human tissue biopsies to drug mixtures, enabling individualized treatment options.
Based on available project data, specific pricing for the end-product is not provided; however, the project received an EU contribution of EUR 3,547,046 for development.
The project specifically aims to create a platform that can be utilized in a highly parallelized fashion to monitor drug effects, suggesting a design intended for scale.
Based on available project data, there are no specific details regarding IP or licensing agreements provided in the summary.
The project period runs from 2022-05-01 to 2026-04-30, indicating it is currently in the development and testing phase.
The project moves away from bulky instruments toward compact and modular devices, which likely simplifies integration into existing laboratory environments.
The consortium consists of 7 partners across 5 countries, showing a balanced mix of 3 universities, 2 research organizations, and 2 industry partners. With an industry ratio of 29% and the inclusion of an SME, the project has a clear bridge between academic research and commercial application, coordinated by Universitaet Bielefeld.
Contact Universitaet Bielefeld regarding the DeLIVERY MPS platform
Contact us to explore licensing opportunities for this MPS imaging technology.
